Gianfranco Nazzi – CEO, Almirall
Almirall CEO Gianfranco Nazzi dives into the new strategic focus of the global biopharmaceutical company with HQ in Barcelona as it seeks to serve the European medical dermatology market. The…
Almirall, S.A. is a Spanish pharmaceutical company, with headquarters in Barcelona, founded in 1943.[4]
In 2016, it generated a total revenue of 859.3 million € [5] and became the leading pharmaceutical company in R&D investment in Spain.
With over 1,975 employees (2016), it has a presence, through its 13 affiliates in Europe and the United States.
Almirall collaborates with various public and private entities, such as the Centro Superior de Investigaciones Científicas (CSIC), the Instituto de Investigación Biomédica and the Parc Científic de Barcelona in Spain. Highlighted among the international alliances are those with the Imperial College of London (United Kingdom) and the National Institute of Health (NIH) in the United States. Almirall participated in the creation of the Barcelona Respiratory Network Foundation. In Europe, the company has contributed in several projects with the Innovative Medicines Initiative (IMI).
Almirall CEO Gianfranco Nazzi dives into the new strategic focus of the global biopharmaceutical company with HQ in Barcelona as it seeks to serve the European medical dermatology market. The…
Rui Ferreira Dos Santos, country manager for Spanish pharmaceutical company, Almirall provides readers with an update on the company’s new medicines and how their global strategy to become dermatology specialists…
Bertil Lindmark, Almirall’s chief scientific officer, discusses the state of R&D in Spain today and outlines the key strategies the company is taking to provide valuable medicines and cutting-edge technologies…
Eduardo Sanchiz took over as CEO of Spain’s flagship pharmaceutical company Almirall in 2011, after Jorge Gallardo stepped down in this role while staying as Chairman of the Board. Many…
Israel Garcia, general manager of Spain for Almirall, discusses market access issues in the company’s home country and highlights the affiliate’s commitment to internal R&D. What was the reason for…
Almirall Portugal stopped all commercial activity in 2011 to focus only on the market access of new, innovative products being introduced through the organization’s active R&D pipeline. Country Manager Rui…
Having only arrived on the market last year, the GM of Almirall in Canada explains the company’s regulatory struggles, the utilization of Almirall’s global R&D infrastructure in Canada as well…
Almirall was opened through the acquisition of Hermal in 2007. What impact did that have on Almirall’s operations in central Europe, and where does Austria fit in Almirall’s picture today?…
Please can you give us a brief rundown of the last few years in the Mexican pharmaceutical and how the various regulation changes such as the new drug registration process…
The UK is leading the biotech turn, and is recognized as the largest biotech market in Europe. Why did Almirall only decide to enter this market until late 2007? Almirall…
Through a merger between INC Research and inVentiv Health in 2018, Syneos Health has become the industry’s only fully integrated biopharmaceutical solutions organisation which includes one of the world’s top…
Stefanie Granado, director general of Takeda Iberia recounts the opportunities available for Takeda in Spain following its acquisition of Shire. She also discusses Takeda’s local acquisition of TiGenix, handing Takeda…
José Herraez, general manager of Beckman Coulter in Iberia, sheds light on the special features of the Danaher business model, and how that has aided his personal growth. Herraez also…
Jesús Donado, CEO of B. Braun Spain introduces the company’s strong footprint in Spain, as a manufacturing hub and a global centre of excellence for the company. Donado also discusses…
Margarita Alfonsel, general secretary of Fenin, offers her perspective on the state of the MedTech industry in Spain, the changing dynamics between the public and private sector, and the issues…
Esteve has long been a family-run business, though in early 2018 the Spanish champion decided to make a daring, though calculated, move and positioned the then CCO of Lundbeck, Staffan…
Despite the Spanish economy and pharmaceutical market’s steady growth, many local players are becoming cognizant of the limitations and risks of operating within a single market. Therefore, these small to…
Jaime Vives, managing director of Roche Diagnostics in Spain, discusses the digital solutions Roche Diagnostics is trying to roll out in Spain, the challenges involved, and the potential implications of…
Francisco Coll, CEO of Quinton, explains the background behind the company’s seawater therapies and how they are expanding this originally French brand internationally. Coll also sheds light on his strategy…
Alba Vergés, Minister of Health of Catalonia, highlights her key priorities within the thriving region of Catalonia as well as the factors that have created a unique ecosystem. Furthermore, she…
Lab Seid is a family owned pharmaceutical company based in Barcelona, specialising in branded out of patent products in the field of women’s health. Seid’s general manager, Joaquín Vilá, discusses…
Ines Perea, general manager for Spain and Portugal at Jazz Pharmaceuticals, a global biopharmaceutical company dedicated to developing life-changing medicines for people with limited or no options in the areas…
See our Cookie Privacy Policy Here
